Mutant Pattern of P53 Predicts Local Recurrence and Poor Survival Rate in Gastric Cancer

Overview

Journal Histol Histopathol

Specialties Anatomy & Histology
Pathology

Date 2023 Feb 27

PMID 36847420

Authors

Yumin Chung

Hyoun Wook Lee

Jung Ho Park

Chang Hak Yoo

Byung Ho Son

Kyungeun Kim

Affiliations

Soon will be listed here.

Abstract

Background: TP53 mutation is a poor prognostic factor for various organ malignancies such as colorectal cancer, breast cancer, ovarian cancer, hepatocellular carcinoma, lung adenocarcinoma and clinical pathologists previously evaluated it using immunohistochemistry for p53. The clinicopathologic significance of p53 expression in gastric cancer remains unclear due to inconsistent classification methods.

Methods: Immunohistochemistry for p53 protein was performed using tissue microarray blocks generated from 725 cases of gastric cancer, and p53 expression was divided into three staining patterns using a semi-quantitative ternary classifier: heterogeneous (wild type), overexpression, and absence (mutant pattern).

Results: Mutant pattern of p53 expression had a male predominance, greater frequency in cardia/fundus, higher pT stage, frequent lymph node metastasis, local recurrence clinically, and more differentiated histology microscopically compared with wild type. In survival analysis, p53 mutant pattern was associated with worse recurrent-free survival and overall survival rates, and significance was maintained in subgroup analysis of early versus advanced gastric cancers. In Cox regression analysis, p53 mutant pattern was a significant predicting factor for local recurrence (relative risk (RR=4.882, p<0.001)) and overall survival (RR=2.040, p=0.007). The p53 mutant pattern remained significant for local recurrence (RR=2.934, p=0.018) in multivariate analyses.

Conclusions: Mutant p53 pattern on immunohistochemistry was a significant prognostic factor for local recurrence and poor overall survival in gastric cancer.

Citing Articles

Mutant Pattern of p53 as a Feasible Predictor of Distant Metastasis Following Curative Gastrectomy for Advanced-stage Gastric Cancer.

An Q, Miao L, Wu J, Ma J J Cancer. 2025; 16(3):860-875.

PMID: 39781338 PMC: 11705056. DOI: 10.7150/jca.98563.

PABPC1 Silencing Inhibits Gastric Cancer Cell Proliferation, Metastasis, and EMT Via the PI3K/AKT Pathway.

Fang J, Zhang Q, Wang Q Biochem Genet. 2024; .

PMID: 39729165 DOI: 10.1007/s10528-024-11008-9.

Endometrioid ovarian carcinoma landscape: pathological and molecular characterization.

de Nonneville A, Kalbacher E, Cannone F, Guille A, Adelaide J, Finetti P Mol Oncol. 2024; 18(10):2586-2600.

PMID: 38923749 PMC: 11459045. DOI: 10.1002/1878-0261.13679.

Clinical, pathological, and comprehensive molecular analysis of the uterine clear cell carcinoma: a retrospective national study from TMRG and GINECO network.

Nigon E, Lefeuvre-Plesse C, Martinez A, Chauleur C, Lortholary A, Favier L J Transl Med. 2023; 21(1):408.

PMID: 37353806 PMC: 10288685. DOI: 10.1186/s12967-023-04264-7.

References

Alexa M, Hasenburg A, Battista M . The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment Decisions. Cancers (Basel). 2021; 13(6). PMC: 8005218. DOI: 10.3390/cancers13061478. View

Ando K, Oki E, Saeki H, Yan Z, Tsuda Y, Hidaka G . Discrimination of p53 immunohistochemistry-positive tumors by its staining pattern in gastric cancer. Cancer Med. 2014; 4(1):75-83. PMC: 4312120. DOI: 10.1002/cam4.346. View

. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513(7517):202-9. PMC: 4170219. DOI: 10.1038/nature13480. View

Cole A, Dwight T, Gill A, Dickson K, Zhu Y, Clarkson A . Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing. Sci Rep. 2016; 6:26191. PMC: 4870633. DOI: 10.1038/srep26191. View

Cristescu R, Lee J, Nebozhyn M, Kim K, Ting J, Wong S . Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015; 21(5):449-56. DOI: 10.1038/nm.3850. View

Fondevila C, Metges J, Fuster J, Grau J, Palacin A, Castells A . p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer. 2004; 90(1):206-15. PMC: 2395306. DOI: 10.1038/sj.bjc.6601455. View

Hwang H, Nam S, Park H, Park Y, Koh J, Na H . Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer. J Pathol Transl Med. 2020; 54(5):378-386. PMC: 7483024. DOI: 10.4132/jptm.2020.06.01. View

Kim K, Kim N, Choi Y, Kim W, Yoon H, Shin C . Different effects of p53 protein overexpression on the survival of gastric cancer patients according to Lauren histologic classification: a retrospective study. Gastric Cancer. 2021; 24(4):844-857. DOI: 10.1007/s10120-021-01163-y. View

Kobel M, Reuss A, du Bois A, Kommoss S, Kommoss F, Gao D . The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol. 2010; 222(2):191-8. DOI: 10.1002/path.2744. View

10.

Kobel M, Piskorz A, Lee S, Lui S, Lepage C, Marass F . Optimized p53 immunohistochemistry is an accurate predictor of mutation in ovarian carcinoma. J Pathol Clin Res. 2016; 2(4):247-258. PMC: 5091634. DOI: 10.1002/cjp2.53. View

11.

Li V, Li K, Li J . TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database. J Cancer Res Clin Oncol. 2018; 145(3):625-636. DOI: 10.1007/s00432-018-2817-z. View

12.

Munro A, Lain S, Lane D . P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer. 2005; 92(3):434-44. PMC: 2362083. DOI: 10.1038/sj.bjc.6602358. View

13.

Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J . The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res. 2006; 12(4):1157-67. DOI: 10.1158/1078-0432.CCR-05-1029. View

14.

Raffone A, Travaglino A, Cerbone M, De Luca C, Russo D, Di Maio A . Diagnostic accuracy of p53 immunohistochemistry as surrogate of TP53 sequencing in endometrial cancer. Pathol Res Pract. 2020; 216(8):153025. DOI: 10.1016/j.prp.2020.153025. View

15.

Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N . The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol. 2005; 23(30):7518-28. DOI: 10.1200/JCO.2005.00.471. View

16.

Schoop I, Saboor Maleki S, Behrens H, Kruger S, Haag J, Rocken C . p53 immunostaining cannot be used to predict TP53 mutations in gastric cancer: results from a large Central European cohort. Hum Pathol. 2020; 105:53-66. DOI: 10.1016/j.humpath.2020.09.006. View

17.

Singh N, Piskorz A, Bosse T, Jimenez-Linan M, Rous B, Brenton J . p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. J Pathol. 2019; 250(3):336-345. DOI: 10.1002/path.5375. View

18.

Sohn B, Hwang J, Jang H, Lee H, Oh S, Shim J . Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. Clin Cancer Res. 2017; 23(15):4441-4449. PMC: 5785562. DOI: 10.1158/1078-0432.CCR-16-2211. View

19.

Talhouk A, McConechy M, Leung S, Li-Chang H, Kwon J, Melnyk N . A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015; 113(2):299-310. PMC: 4506381. DOI: 10.1038/bjc.2015.190. View

20.

Wei K, Jiang L, Wei Y, Wang Y, Qian X, Dai Q . The prognostic significance of p53 expression in gastric cancer: a meta-analysis. J Cancer Res Clin Oncol. 2014; 141(4):735-48. DOI: 10.1007/s00432-014-1844-7. View